Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement Equity Offering On January 7, 2026, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agre
Other Events. On January 7, 2026, the Company issued a press release announcing that it priced the Equity Offering and the Convertible Notes Offering. A copy of
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Equity Underwriting Agreement, dated as of January 7, 2026, between Arrowhead Pharma